A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Spain, as Part of Local Clinical Practice

CompletedOBSERVATIONAL
Enrollment

465

Participants

Timeline

Start Date

July 28, 2022

Primary Completion Date

July 4, 2024

Study Completion Date

July 4, 2024

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

Semaglutide

Participants will be treated with commercially available oral semaglutide according to local label and to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available oral semaglutide has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the participant in this study.

Trial Locations (2)

28033

Master Centre for Spain, Madrid

08025

Master Centre for Spain, Barcelona

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY